

## Cambodia : Cambodia Rapid Immunization Support Project

### 1. Project Information

Project ID:	P000521	Instrument ID:	L0521A
Member:	Cambodia	Region:	South-Eastern Asia
Sector:	CRF-Public Health	Sub-sector:	N/A
Instrument type:	<input checked="" type="checkbox"/> Loan:50.00 US Dollar million <input type="checkbox"/> Guarantee	Lead Co-financier (s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Ministry of Economy and Finance, Cambodia
Implementing Entity:	Ministry of Health, Cambodia		
Project Team Leader:	Ankur Agrawal		
Responsible DG:	Rajat Misra		
Responsible Department:	INF1		
Project Team Members:	Yang Shuai, OSD - Environment & Social Development Specialist; Jinghui Li, Team Member; Bernardita Saez, Project Counsel; Liu Yang, Alternate Counsel; Shodi Nazarov, OSD - Financial Management Specialist; Rabindra Shah, OSD - Procurement Specialist; Jinghui Li, Project admin		
Completed Site Visits by AIIB:	Mar, 2023 ADB and AIIB conducted virtual implementation support mission in March, 2023		
Planned Site Visits by AIIB:	Sep, 2023 Next mission will be in September, 2023.		
Current Red Flags Assigned:	1		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:			
Previous Red Flags Assigned Date:			

### 2. Project Summary and Objectives

The objective of the Project is to increase access to eligible COVID-19 vaccines for target population groups in Cambodia.

The Project will support the procurement of 14.5 million doses safe and effective vaccines against COVID-19. It will contribute to the government's goal of strengthening population immunity by providing booster doses and primary vaccination to children below 5 years of age. The Project is co-financed with the Asian Development Bank (ADB) under its rapid response component of ADB's Asia Pacific Vaccine Access Facility (APVAX).

The total Project cost is USD 153.5 million, for which AIIB finances USD50 million (32.57 percent), ADB finances USD95 million (61.89 percent) and the Government of Cambodia (GoC) finances the remaining USD8.5 million (5.54 percent). The loan proceeds from AIIB and ADB will finance expenditures relating to the procurement of COVID-19 vaccines that meet the APVAX eligibility criteria. The GoC contribution will cover financing charges, personnel

expenditure and vaccine storage and transportation expenses.

### 3. Key Dates

Approval:	Mar. 24, 2022	Signing:	Apr. 22, 2022
Effective:	Sep. 29, 2022	Restructured (if any):	
Orig. Closing:	Dec. 31, 2024	Rev. Closing (if any):	

### 4. Disbursement Summary (USD million)

Contract Awarded:		Cancellation (if any):	0.00
Disbursed:	14.27	Most recent disbursement (amount/date):	14.27/Mar. 03, 2023
Undisbursed:	35.73	Disbursement Ratio (%) <sup>1</sup> :	28.55

### 5. Project Implementation Update

Through retroactive financing, a total amount of USD14.27 million (28.6% of loan amount) has been disbursed for those contracts awarded prior to the Loan Agreement signing. Given the evolution in the global Covid-19 pandemic situation, large scale procurement of booster doses for adult and of pediatric Covid-19 vaccines for children under the age 5 is not envisaged any more. The mission undertaken in March 2023 confirmed that the Government's intention to request project restructuring to incorporate Project Investment Component under ADB's APVAX. Based on the government's detailed proposal, ADB and AIIB would consider the restructuring proposal.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	The retroactive financing of ADB and AIIB has been used to support the roll-out of 6 million doses, through a 2-dose primary vaccination series to approximately 3 million people.	Since the project has been categorized as C for all E&S aspects under ADB's Safeguard Policy Statement (SPS), no standalone safeguards monitoring report is required. A summary of safeguards compliance with supporting documents pertaining to adequacy of COVID-19 immunization waste management system will be provided in the consolidated annual reports due in Q2 2023.	A total of 6 million doses have been procured till now - 2 million doses under AIIB financing and 4 million doses under ADB financing.

#### Financial Management:

The Government of Cambodia established two advance accounts on 14 July 2022. The sub-accounts are yet to be opened. MEF will inform ADB and AIIB when the accounts have been opened. An annual audited project financial

<sup>1</sup> Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

---

statement (APFS) for FY2022 is due for submission on June 30, 2023 and subsequently throughout duration of the project. Since no disbursements were made in 2022, MOH may consider requesting ADB a deferment of the submission of the first APFS and consolidate APFS for FY2022 and FY2023 for submission in June 2024. The request to defer the first APFS and consolidated submission may be sent to ADB and AIIB by May 15, 2023. The audit will cover all areas of a standard audit (including audit opinion on the use of funds via retroactive financing) and will follow the MEF and Cambodian Public Sector Accounting Standards in terms of specific presentation of retroactive amounts in the financial statements. The government will present the status of the financial management action plan by the end of March 2023.

---

**6. Status of the Grievance Redress Mechanism (GRM)**

GRM exists at the Government of Cambodia which is able to receive and address complaints.

---

**7. Results Monitoring (please refer to the full RMF, which can be found on the last page of this PIMR)**

Results shall be monitored in due course.

---

**Remarks:**

---

Project Indicators	Objective	Indicator level	Unit of Measure	Cumulative Target Values										Frequency	Responsibility	Comments			
				Baseline		2022		2023		2024		End Target							
				Year	Value	Target	Actual	Target	Actual	Target	Actual	Year	Target				Actual		
Additional 10.12 million people in target populations vaccinated or boosted against COVID-19, disaggregated by sex		Project	Number	2022	17 million	17 million	23.1					27.12			27.12 million		Once	Ministry of Health	

Project Intermediate Indicators	Indicator level	Unit of Measure	Cumulative Target Values													Frequency	Responsibility	Comments	
			Baseline		2021		2022		2023		2024		2025		End Target				
			Year	Value	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Year				Target